Komori
Fuji Pharma (4554) · InitiativeRestated

Enhancing Cost Competitiveness to Compete with Global Players

First written in FY2016-Q3. 10 of 11 entries say "Restated". Latest entry: FY2019-Q3.

11entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016-Q3 – FY2019-Q32016: 120162017: 420172018: 320182019: 32019
Same theme, other companies
Quality, Cost Competitiveness and Process Development for Generic PharmaceuticalsA theme 7 companies write about · 0 as a headwind · 8 as a tailwind

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2019-Q3RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  2. FY2019-Q2RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  3. FY2019-Q1RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  4. FY2018-Q3RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  5. FY2018-Q2RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  6. FY2018-Q1RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  7. FY2017RestatedAnnual report

    「We will work to improve factory efficiency and productivity.」

    The company continues to link strengthening cost competitiveness against global players with factory efficiency improvements and higher productivity.
  8. FY2017-Q3RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  9. FY2017-Q2RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  10. FY2017-Q1RestatedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    The company continues to regard strengthening cost competitiveness against global players as an urgent management priority.
  11. FY2016-Q3First statedAnnual report

    「Strengthening cost competitiveness to compete with global players」

    Identified as an urgent management priority in the generic pharmaceuticals business.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuji Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.